



PATENT  
Customer No. 22,852  
Attorney Docket No. 09367.0018-04000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of	)	Group Art Unit: 1624
Gustave Bergnes et al.	)	
	)	Examiner: Tamthom Ngo Truong
Application No. 09/724,897	)	
	)	Confirmation No.: 1088
Filed: November 28, 2000	)	
	)	
For: METHODS AND COMPOSITIONS	)	
UTILIZING QUINAZOLINONES	)	

Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450  
Mail Stop RCE

Sir:

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents on the attached listing. This Information Disclosure Statement is being filed before the mailing date of a first Office Action after the filing of a Request for Continued Examination in the above-referenced application.

Copies of the listed foreign and non-patent literature documents are attached. Copies of the U.S. patent publications are not enclosed.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim

in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.


If there is any fee due in connection with the filing of this Statement, please charge the fee to Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Date: January 18, 2006


By: \_\_\_\_\_



Lauren L. Stevens  
Reg. No. 36,691

## INFORMATION DISCLOSURE CITATION

Atty. Docket No.	0937.0018-04000	Appln. No.	09/724,897
Applicants	Gustave Bergnes et al.		
Filing Date	November 28, 2000	Group:	1624



## U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
1.	6,136,812	10/24/00	Chenard et al.			
2.	2002/0169159 A1	11/14/02	Medina et al.			
3.	2003/0055054 A1	03/20/03	Medina et al.			
4.	2002/0165221 A1	11/07/02	Baxter et al.			
5.	2004/0077667 A1	04/22/04	Matsuoka et al.			
6.	4,734,419	03/29/88	Hashimoto et al.			
7.	2003/0119854 A1	06/26/03	Schall et al.			
8.	6,518,277 B1	02/11/03	Sadhu et al.			

## FOREIGN PATENT DOCUMENTS

Examiner Initial*	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
1.	WO 01/81346 A2	11/01/01	WIPO			
2.	WO 93/20055 A1	10/14/93	WIPO			
3.	WO 96/28430 A1	09/19/96	WIPO			
4.	WO 95/19169 A2	07/20/95	WIPO			
5.	EP 0 509 643 A1	10/21/92	Europe			
6.	WO 93/19051 A1	09/30/93	WIPO			


## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages etc.)

Examiner Initial*	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages etc.)
1.	Wagner "Synthesis and Biological Evaluation of Some Derivatives of Pyrido[3, 2-d]pyrimidine" <i>Acta Poloniae Pharmaceutica - Drug Research</i> 51(4-5): 359-363 (1994)
2.	Ghorab, "Synthesis of Some New Thiadiazole, Selena, Triazine, Thiazole and Cyanopyridine Derivatives with Assay for Their Antitumor Activity," <i>Phosphorus, Sulfur, and Silicon</i> , 112: 7-17 (1996)

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce

## INFORMATION DISCLOSURE CITATION

Atty. Docket No.	0937.0018-04000	Appln. No.	09/724,897
Applicants	Gustave Bergnes et al.		
Filing Date	November 28, 2000	Group:	1624



Examiner Initial*	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages etc.)	
3.		Ghorab et al., "Synthesis and effect of some new [1,2,4]triazolo[4,3-a]quinazolin-5(4H)-ones and related compounds on Ehrlich Ascites Carcinoma cells," <i>Acta Pharm.</i> , 49: 1-10 (1999)
4.		Jiang et al., "Synthesis and Biological Evaluation of 2-Styrylquinazolin-4(3H)-ones, a New Class of Antimitotic Anticancer Agents Which Inhibit Tubulin Polymerization," <i>J. Med. Chem.</i> , 33: 1721-1728 (1990)
5.		Ghosh, "Quinazolines. Part I.," <i>J. Indian Chemical Society</i> , XIV: 411-413 (1937).
6.		Mayer et al, "Small Molecule Inhibitor of Mitotic Spindle Bipolarity Identified in a Phenotype-Based Screen," <i>Science</i> , 286: 971-974 (1999).

Examiner	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce